

1 **A Population-Based Cross-Sectional Investigation of COVID-19 Hospitalizations and Mortality**
2 **Among Autistic People**

3

4 Dewy Nijhof*¹, Filip Sosenko*¹, Daniel Mackay¹, Michael Fleming¹, Bhautesh D Jani¹, Jill Pell¹, Chris
5 Hatton², Deborah Cairns¹, Angela Henderson¹, Laura Ward¹, Ewelina Rydzewska³, Maria Gardani³,
6 Elliot Millington¹, Craig Melville¹, on behalf of the CVD-COVID-UK/COVID-IMPACT Consortium

7 *Joint first author

8 ¹University of Glasgow, School of Mental Health and Wellbeing

9 ²Manchester Metropolitan University, Faculty of Health and Education

10 ³University of Edinburgh, School of Health in Social Science

11

12 Corresponding author: Dewy Nijhof, dewy.nijhof@glasgow.ac.uk

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30 **Abstract**

31 **Background:** Current evidence suggests the possibility that autistic people may be at more risk of
32 COVID-19 infection, hospitalisation, and mortality than the general population. Previous studies,
33 however, are either limited in scale or do not investigate potential risk factors. Whilst many risk factors
34 have been speculated to be responsible for severe COVID-19, this research has focused on general
35 population samples. **Methods:** Using data-linkage and a whole-country population, this study
36 modelled associations between autism and COVID-19 hospitalisation and mortality risk in adults,
37 investigating a multitude of clinical and demographic risk factors. **Results:** Autistic adults had higher
38 rates of hospitalisation, Standardised Incident Ratio 1.6 in 2020 and 1.3 in 2021, and mortality,
39 Standardised Mortality Ratio 1.52 in 2020 and 1.34 in 2021, due to COVID-19 than the general
40 population. In both populations, age, complex multimorbidity and vaccination status were the most
41 significant predictors of COVID-19 hospitalisation and mortality. Effects of psychotropic medication
42 varied by class. **Conclusions:** Although similar factors exhibited a positive association with heightened
43 risk of severe COVID-19 in both the autistic and general populations, with comparable effect sizes,
44 mortality rates were elevated among the autistic population as compared to the general population.
45 Specifically, the presence of complex multimorbidity and classification of prescribed medications may
46 emerge as particularly significant predictors of severe COVID-19 among individuals within the autistic
47 population due to higher prevalence of complex multimorbidity in the autistic population and
48 variability in the association between medication classes and severe COVID-19 between both
49 populations, though further research is needed.

50

51 **Keywords** Autism Spectrum Disorder, ASD, COVID-19, Morbidity, Hospitalisation, Mortality,
52 Population study

53

54

55

56

57

58

59

60

61

62 **Introduction**

63 In the UK, the earliest COVID-19 cases were identified in late January 2020 and a pandemic was
64 officially declared in March 2020 (1). Increasing evidence suggests increased risk of susceptibility and
65 severe disease progression of COVID-19 for certain conditions (2,3). For example, conditions such as
66 diabetes and obesity were deemed risk factors (2). Subgroups within the population have been shown
67 to be disproportionately at risk of COVID-19 but the full extent of these risk factors is unclear (4). Most
68 research has focused on ethnic subpopulations or high-risk patient groups, but little is known about
69 the risks of COVID-19 for autistic people¹.

70

71 Autism Spectrum Disorder (ASD) is defined as a neurodevelopmental disorder. Its main characteristics
72 are differences in social communication and interaction and repetitive and restrictive behaviours,
73 including differences in sensory preferences (5). Whilst several genetical and immunological
74 characteristics of autism have been hypothesised to affect COVID-19 infection, severity, and mortality
75 risk (6–8), few studies have focused on differences in the clinical profiles of autistic people and the
76 general population. Both physical and mental health conditions, such as obesity (2,3), gastrointestinal
77 symptoms (3) and mental health conditions (9,10) have been associated with increased COVID-19
78 infection, disease severity and mortality in the general population. Several of these conditions often
79 co-occur alongside autism (11,12). Specifically, psychotic disorders and mood disorders are more
80 commonly experienced by autistic people (12) and have been linked with increased risk of COVID-19
81 mortality in the general population (9). It is further argued by some that sensory difficulties
82 experienced by autistic people can hinder their ability to adhere to COVID-19 measures, such as
83 wearing personal protective equipment (PPE) or strict hygiene rules, thereby increasing the potential
84 for exposure to sources of infection (13,14). Similarly, differences in communication and social
85 isolation can impact the ability to understand and follow COVID-19 related advice and affect help-
86 seeking behaviours and patient-clinician communication in relation to health (13,14).

87

88 Furthermore, long-term conditions and multimorbidity prevalence is often accompanied by
89 polypharmacy, the use of multiple medicines, which has been shown to contribute to increased
90 COVID-19 morbidity in the general population (15,16) but has not been investigated in autistic
91 populations. Yet, polypharmacy and more particularly prescription of antipsychotics are prevalent
92 both amongst autistic children (17) and autistic adults (18,19). Commonly prescribed medications,
93 including antipsychotics, antidepressants, and anticholinergic medication, are known to have the

¹ Throughout this paper we use identity-first language or neutral terms ('autistic people' or 'people on the autism spectrum') rather than person-first language as a result of the article by Kenny et al. (53) highlighting the preference for identity-first language by the majority of autistic people and their families.

94 potential to increase the risk of pneumonia through immunosuppressive and other protective
95 mechanisms (20). Moreover, antipsychotics have been shown to exert anti-inflammatory effects and
96 disrupt immune responses (21), which may contribute even further to adverse COVID-19 outcomes.
97 Indeed, several studies (22,23) and a meta-analysis (9) found increased risk of COVID-19 mortality
98 associated with exposure to antipsychotics in the general population. Furthermore, recent research
99 has raised the issue of potential adverse outcomes due to drug-drug interactions of prescribed
100 medications and COVID-19 pharmacotherapies (24,25).

101

102 Few studies have investigated the association between autism and COVID-19 and results are
103 inconsistent. One study investigating 36 autistic children in a residential facility did not find higher
104 prevalence nor severity of COVID-19 in autistic young adults, though it should be mentioned that
105 study controls (n=35) were of older age than the autistic group (6). Further, this study did not
106 differentiate between young adults with autism only and young adults with co-occurring autism and
107 intellectual disabilities (ID). Previous research suggests that people with ID are at higher risk of
108 severe COVID-19 (27,28) and thus results may be confounded. Moreover, facilities in which
109 individuals live in close proximity have been found to increase infection rates (29), confounding
110 results even further. A meta-analysis found increased risk of COVID-19 mortality in autistic people
111 only in unadjusted estimates and no evidence of increased intensive care admissions, but did not
112 separate autism from ID or other developmental disorders (9). In contrast, a population-based study
113 found that autistic males over 16 years had higher COVID-19 hospitalisation rates after stratifying for
114 age, gender and morbidities that have been shown to increase COVID-19 infection rates compared
115 to the general population (30).

116 As such, there is conflicting evidence regarding the risk of COVID-19 infection and outcome severity
117 amongst autistic people. To the best of our knowledge, no studies have investigated whether this risk
118 extends to COVID-19 mortality. Moreover, whilst previous studies speculated on the underlying
119 causes of increased risk, none have systematically studied clinical risk factors for COVID-19 in the
120 autistic population. Using a country-wide sample, the current study aimed to investigate whether
121 there are differences in COVID-19 hospitalisation and mortality rates between autistic people and the
122 general population. Furthermore, this study aimed to explore the association between demographic
123 and clinical risk factors and severe COVID-19 in the autistic population.

124 **Methods**

125 ***Study Design***

126 This was a cross-sectional study using a whole-country population. Data was subdivided into two time
127 periods: (1) including the month in which the first lockdown started in the UK, 1 March 2020, to 31
128 December 2020; (2) 1 January 2021 to 31 December 2021. This division was made due to the
129 vaccination programme not coming into full effect until 2021. While the first vaccination was received
130 on 8 December 2020, due to vaccination priorities and logistics it is reasonable to assume that the
131 majority of the study population had not received a COVID-19 vaccination in 2020. However, by the
132 end of 2021, a greater proportion of the population had likely been afforded the opportunity to
133 receive at least one COVID-19 vaccination. Consequently, COVID-19 rates in 2021 may vary
134 significantly from those in 2020.

135

136 ***Data sources and definitions***

137 This study was conducted on behalf of the CVD-COVID-UK/COVID-IMPACT Consortium (31)
138 (coordinated by the BHF Data Science Centre). The following datasets were used: GPES Data for
139 Pandemic Planning and Research (GDPPR), Hospital Episode Statistics (HES), COVID-19 Second
140 Generation Surveillance System (SGSS), Vaccination Events (VE), Civil Registry Deaths from the ONS
141 (ONS-D), NHS BSA Dispensed Medicine (NHS BSA). The GDPPR, HES, SGSS, VE and NHS BSA datasets
142 are updated through the National Health Service (NHS) and processed by NHS England, after which
143 the data is available for secondary uses, such as research. The ONS dataset is updated through the
144 Office for National Statistics (ONS). Approvals were obtained from the research consortium and from
145 the University of Glasgow Ethics Committee.

146 Long-term conditions (LTCs) were identified using a list of 35 common conditions in the general UK
147 population (32) using phenotypes sourced from the Cambridge Multimorbidity Score, using the GDPPR
148 and HES datasets (33). This list includes conditions that have previously been identified as risk factors
149 for COVID-19 infection and severity, for example obesity, diabetes, and hypertension (2). The list
150 includes both physical and mental conditions but excludes autism. Complex multimorbidity was
151 defined by the presence of at least three of those 35 LTCs of which at least one was physical (34).
152 Polypharmacy was defined as the concurrent use of five prescription medications or more (35).
153 Polypharmacy, use of antipsychotics, antidepressants, anticonvulsants, and psychotropic medication
154 were identified using British National Formulary (BNF) codes. Prescribing data was examined if it fell
155 within the following parameters: dispensed within 15 days before the date of testing positive for
156 COVID-19 (cut-off date) and within 240 days before this cut-off date (35).

157 In the context of this study, severe COVID-19 included those who had a positive COVID-19 laboratory
158 test and were hospitalised for COVID-19 or died from COVID-19 within 28 days from the test or died
159 without a positive test, but COVID-19 is listed as a cause of death on their death certificate (any
160 diagnostic position).

161 **Population**

162 The study covered the whole adult (i.e., over 18 years old) population of England who were alive on 1
163 January 2020 and had at least one primary care record (for the purpose of establishing their autism
164 status). Autistic individuals were identified using SNOMED CT diagnosis codes in the primary care
165 dataset (GDPPR). Some evidence suggests that people with ID have a larger risk of severe COVID-19
166 (27,28). Further, research suggests that there may be complex interactions at play in relation to
167 mortality and causes of mortality when it comes to comorbid autism-ID (36). As such, this study opted
168 to investigate severe COVID-19 in autism only. Participants who had diagnoses for both autism and ID
169 were included in the comparison group to control for potential confounding (having ID is a major risk
170 factor for COVID-19 hospitalisation or death (27). Although there is a possibility that this may
171 marginally reduce any differences found between autistic people and the comparison group, we
172 maintain the stance that as a result of this decision, any inferences drawn from this study will be more
173 generalisable to autistic people without intellectual disabilities -which remains the main focus of the
174 study.

175 The whole population consisted of 180,860 (of which 28.5% female) autistic people and 48,383,120
176 (of which 50.4% female) people in the comparison group, hereafter referred to as general population.
177 Age distribution in the two populations differed significantly, with a median age of 47 [interquartile
178 range (IQR) 30] years in the general population and 26 [IQR 12] in the autistic population (t-test, p -
179 value <0.001). This corresponds to known low levels of identification or recording of autism in primary
180 care records for people aged over 30 years old (37) as well as diagnostic advances and autism
181 awareness over the years (38). Demographic and health characteristics of the study participants are
182 shown in *Table 1*. Characteristics for the 35 long-term conditions for both the whole population and
183 analysis sample- (i.e., those infected with and hospitalised for COVID-19) can be found in the *Appendix*.

184 [TABLE 1]

185 From this whole population, participants were included in the analysis if they met at least one of two
186 criteria: (1) they had a registered positive COVID-19 laboratory test (identified through GDPPR) or (2)
187 COVID-19 was listed as a cause of death (either primary or other contributing causes using ICD-10 code
188 U07.1 or U07.2) on their death certificate. In the case of multiple positive tests, the first instance was

189 used. Information about LTCs, vaccination status, and prescribed medications were extracted using
190 the time of positive test result.

191 **Data Analysis**

192 Data was analysed within NHS England's Secure Data Environment service for England, made available
193 via the British Heart Foundation Data Science Centre's CVD-COVID-UK/COVID-IMPACT Consortium
194 (31), using a combination of Python (v3.7), SQL, and R (v4.03) scripts. The analysis was performed
195 according to a pre-specified analysis plan published on GitHub (39), along with the phenotyping and
196 analysis code.

197 Demographic (age, sex, ethnicity, Index of Multiple Deprivation (IMD)) and health characteristics (LTCs,
198 complex multimorbidity, vaccination status, prescribed medications) were explored and compared
199 using means, standard deviations, and t-tests for continuous data and frequency, percentages, and χ^2 -
200 tests for categorical data. Standardised Incident Ratios (SIRs) and Standardised Mortality Ratios (SMRs)
201 were calculated for 2020 and 2021 separately. SIRs were also calculated for hospitalisation (while
202 positive for COVID-19) and severe COVID-19 (hospitalisation or death due to COVID-19). A binary
203 logistic regression model was used to model prediction of severe COVID-19 infection using
204 demographic and health factors as predictors. Note that modelling of antipsychotic, antidepressant,
205 and anticonvulsant medication did not control for diagnosis of related mental health conditions due
206 to the possibility of prescription of these medications for unrelated issues. There is evidence to suggest
207 that overprescription, particularly of psychotropic medications, is a significant issue in relation to
208 autistic adults (37,40) with and without psychiatric conditions (41). Further, though research on these
209 medication classes in autistic people is scarce, limited evidence suggests variable effects regarding
210 efficacy and tolerance of psychotropic medication in autistic people (41).

211 Further hierarchical logistic modelling was used to assess the contribution of each predictor category.
212 Blinder-Oaxaca decomposition analysis was applied to decompose the mean difference in the risk of
213 severe COVID-19 between the two population groups for each of the predictor categories used in the
214 regression modelling (42).

215 Logistic regression was chosen as the main modelling technique rather than survival analysis due to
216 its allowance for a larger number of records to be included. (Individuals who had a PCR test already in
217 hospital, and those who died without a PCR test, cannot be included in survival analysis). Still, survival
218 analysis in the form of a Cox proportional hazards model was conducted as a sensitivity test of the
219 logistic modelling.

220 **Results**

221 *Demographics*

222 A total of 32,375 autistic people and 8,425,470 general population individuals were hospitalised with
223 a positive COVID-19 test. Table 1 shows the demographic and health characteristics of autistic
224 people and the general population used in the analysis (i.e., tested positive for COVID-19). Due to
225 the younger age structure in the autistic population, both unadjusted and age-adjusted values are
226 shown. The autistic group had a significantly different population structure, demonstrated by a
227 lower percentage of females, higher chance of living in a deprived area (evidenced by lower mean
228 IMD decile) and a higher percentage of white ethnicity. Autistic adults were equally likely as the
229 general population to be vaccinated for COVID-19. Polypharmacy was more prevalent in the autistic
230 population, with the mean numbers of prescription medications being 5.1 (SD 6.0) compared to 2.9
231 (SD 4.5) for the general population. Similarly, use of psychotropic, antipsychotic, antidepressant and
232 anticonvulsant medications, was higher within the autistic population.

233 Autistic adults were also more likely to experience complex multimorbidity. From the list of 35 most
234 common conditions in the UK, only three were not significantly higher for autistic adults
235 (bronchiectasis, chronic kidney disease, and multiple sclerosis; see Appendix for full list). A few
236 conditions stood out due to particularly higher prevalence in the autistic population: stroke/transient
237 ischaemic attack, schizophrenia/bipolar disorder, psychoactive substance misuse, Parkinson's disease,
238 diabetes, depression, dementia, asthma, anxiety/other neurotic disorders, and anorexia/bulimia.

239 *Incidence, mortality and survival analysis*

240 Table 2 shows the SIRs for autistic adults who were hospitalised due to COVID-19 or who classify as
241 having severe COVID-19 (i.e., taking together COVID-19 hospitalisations and COVID-19 deaths). The
242 ratios show a higher incidence of both hospitalisation and severe COVID-19 for autistic adults in
243 comparison to the general population, although a decline over time is visible from 2020 to 2021.

244 [TABLE 2]

245 Table 3 shows the Age Standardised Mortality Rate (ASMR) and Standardised Mortality Rates (SMR).
246 ASMR takes the European Standard Population 2013 as reference and SMR takes the general
247 population from the study sample as reference. Whilst ASMRs were higher for both groups within the
248 study sample, the autistic population had particularly high mortality rates compared to the European
249 Standard Population. Within the study sample, mortality rates for autistic adults were similarly
250 increased compared to the general population. Similar to incidence rates, a decline from 2020 to 2021
251 is visible.

252 [TABLE 3]

253 *Modelling of risk factors*

254 Logistic regression modelling has been employed to investigate risk factors. The final model included
255 two versions sharing core predictor variables and differed only in the aspect of medications. Model A
256 focused on polypharmacy while model B focused on psychotropic medication.

257 Table 4 shows the results from the logistic regression models A and B. For both the autistic and general
258 population, several factors were positively associated with increased risk of severe COVID-19 with
259 similar effect sizes: age, ethnicity, complex multimorbidity (count of long-term conditions),
260 polypharmacy (count of prescription medication), and antipsychotic prescription. Interestingly, the
261 effect of complex multimorbidity varies by the extent of polypharmacy and vice versa. The effect of
262 either risk factor is stronger when the score for the other is low. Again, effect sizes were similar
263 between the two groups.

264 [TABLE 4]

265 Anticonvulsant prescription was significantly but weakly positively associated with increased risk for
266 the general population only. Whereas Asian/Asian British ethnicity was the only ethnicity at risk for
267 the autistic population, Black/Black British ethnicity was most at risk for the general population
268 followed by Other, Asian/Asian British and Mixed ethnicity. Additionally, the effects of ethnicity and
269 antipsychotic prescription on severe COVID-19 risk were more profound for the general population.
270 Effects of long-term condition count were more pronounced for the autistic population. Contrastingly,
271 female sex, Pfizer and Moderna vaccination, and antidepressant prescription were associated with
272 decreased risk of severe COVID-19 for both the autistic and general population. Number of COVID-19
273 vaccination doses and AstraZeneca vaccination were significantly associated with decreased risk for
274 the general population only. Antidepressant prescription effects were more pronounced for the
275 autistic population. Table 5 shows the results from the survival analysis showing similar trends in
276 associations, thus supporting findings from the logistic regression models.

277 [TABLE 5]

278 Hierarchical logistic modelling (Table 6) indicated that age, vaccination status and LTC count were the
279 most important predictors for modelling severe COVID-19 infection in both autistic adults and the
280 general population.

281 [TABLE 6]

282 Figure 1 visualises results from the Blinder-Oaxaca Decomposition analysis to decompose the mean
283 difference in risk of severe COVID-19 between the autistic and general population groups into two
284 components: the endowment effect, showing how much of the mean difference between the autistic
285 and general population group is due to different distributions of the variable, and the coefficient effect,
286 showing how much of the mean difference between the two groups is due to different influences of
287 the same variable. As Figure 1 shows, the difference in non-age-adjusted probability of severe COVID-
288 19 (0.066 in the general population, 0.033 in the autism group) can largely be attributed to the
289 younger age profile of adults with autism.

290 [FIGURE 1]

291 **Discussion**

292 This study aimed to explore COVID-19 in autism by investigating hospitalisation and mortality rates
293 and exploring the association between demographic and clinical risk factors and their contributions to
294 severe COVID-19 in autistic people. Previous studies investigating COVID-19 in autistic people
295 produced conflicting results. Similar to a previous population-based study [34], our findings provide
296 further evidence for the increased risk of hospitalisation (SIR 2020: 1.6, SIR 2021: 1.3) and mortality
297 (SMR 2020: 1.52, SMR 2021: 1.34) of autistic adults due to COVID-19.

298 Exploration of demographic and clinical factors through regression modelling showed similar risk
299 factors for the autistic and general population, with a few exceptions. Whereas all minority ethnicities
300 were predictive of severe COVID-19 for the general population, only Asian/Asian British ethnicity was
301 a significant predictor for the autistic population. This may be due to the different distribution of
302 ethnicity between the two groups, with non-white ethnicities being less prevalent in the autistic
303 population affecting sample size for those ethnicities (see Table 1). Similarly, female sex had a more
304 protective effect for the general population than for the autistic population which may be explained
305 due to the male bias in autism prevalence (43).

306 Number of COVID-19 vaccination doses only differed when not age-adjusted, however, the brands of
307 vaccination had differing effects in the two populations. For both the general and autistic population,
308 most people had received either Pfizer or AstraZeneca. Modelling of the predictors showed that while
309 Pfizer was a significantly protective factor for severe COVID-19 for both populations, AstraZeneca was
310 only significantly protective for the general population. Moderna was received the least by both
311 populations and was found to be the most protective factor out of all predictors. There was no
312 difference in the total number of vaccination doses received by either population.

313 The number of long-term conditions was the most important predictor of severe COVID-19 for the
314 autistic population but not for the general population. Though the current study did not investigate
315 individual associations between the long-term health conditions and COVID-19 hospitalisation and
316 mortality, it is possible that this finding is due to the different clinical profile of the autistic population.
317 Complex multimorbidity in general but particularly mental health conditions such as depression,
318 dementia, anxiety and schizophrenia were more prevalent in the autistic study population. Previous
319 research identified associations between increased risk of COVID-19 mortality and psychotic disorders,
320 mood disorders and substance use disorders (9,10). The finding that the number of long-term
321 conditions emerged as a significant predictor of severe COVID-19 in the autistic population, but not in
322 the general population, underscores the intricate nature of multimorbidity in this group. However,
323 this paper did not delve into the individual associations between long-term health conditions and
324 COVID-19 outcomes. It is plausible that medication regimen, coupled with the presence of
325 multimorbidity, may potentially lead to complex interactions that influence COVID-19 outcomes.
326 Therefore, future research endeavours should aim to untangle the effects of medication regimen and
327 the composition of multimorbidity in the autistic population on COVID-19 outcomes, warranting a
328 separate and focused investigation.

329 Further, survival modelling showed that similarity in the number of prescriptions and the number of
330 long-term conditions decreased the risk of severe COVID-19. In other words, low values of one variable
331 paired with high values of the other were associated with higher risk of severe COVID-19. This may
332 suggest that well-treated conditions and appropriate use of prescription medications may be a
333 protective factor for severe COVID-19. Although this was found for both the autistic and general
334 population, there is evidence to suggest that the health needs of autistic people are sometimes
335 overlooked (44,45) or exacerbated by barriers in accessing medical care (46). Furthermore, despite
336 similar effect sizes in the two populations, mortality rates were higher for the autistic population. Our
337 findings highlight the importance and potentially far-reaching impact of addressing health inequalities
338 experienced by autistic people.

339 Whilst polypharmacy was not included amongst the most important predictors in the hierarchical
340 model for either the autistic or general population, further exploration suggests that this might be due
341 to different effects of the medication class as we found, for both the autistic and general population,
342 antipsychotic medication to be predictive of severe COVID-19 whereas antidepressant medication was
343 protective. Furthermore, antipsychotic prescription was more predictive of severe COVID-19 in the
344 general population whereas antidepressant prescription was more protective for the autistic
345 population. Potentially, this could be due to differences in how these prescriptions are targeted in the
346 two populations. For example, these medication classes are prescribed to autistic people on a more

347 widespread basis with antipsychotics being prescribed in absence of comorbid psychiatric conditions
348 (41) The finding of protective effects of antidepressant prescription corresponds to prior research
349 suggesting lower infection rates and decreased COVID-19 severity in patients using antidepressants in
350 the general population (47,48). Whilst there are contradictory findings, pooled effects seem to
351 indicate a protective effect of antidepressants against severe COVID-19 (47).

352 Due to abovementioned targeting of prescription medications in the autistic population and potential
353 of prescription medications to be used for a multitude of conditions, our study did not match
354 prescribed medications to existing conditions as this would not be an accurate representation of the
355 use of medications in the autistic population. As such, we are unable to ascertain whether there is a
356 potentially mediating effect between medication and condition on severe COVID-19. For example,
357 several studies provide evidence that psychiatric conditions such as schizophrenia, depression and
358 anxiety have higher COVID-19 mortality rates (9,10). Results from the hierarchical modelling suggest
359 that the long-term condition is indeed a more significant risk factor than polypharmacy. However, the
360 classes of medication explored in this study can be prescribed for a multitude of conditions and, thus,
361 were not linked to specific long-term conditions. In addition, there are concerns that there may be
362 adverse reactions of prescription medication and COVID-19 treatments (20). Due to the unavailability
363 of COVID-19 treatment data, this study was unable to ascertain whether prescription medication was
364 taken during the hospital stay and whether there could be potential reactions with COVID-19
365 treatments provided. Additionally, exploring the effects of differing combinations of prescription
366 medication(s) and long-term conditions was beyond the scope of the current study. However, our
367 results suggest that this may be a viable target for future research.

368 **Strengths and limitations**

369 This study has several strengths. The study makes use of a whole-country population of autistic
370 individuals and the general population. This large sample size ensures a representative sample,
371 thereby reducing sampling bias. The combination of the large sample size and the use of validated
372 datasets further strengthens the validity and robustness of the results. Moreover, inclusion criteria for
373 autism are based on clinical diagnoses, using both older and newer diagnosis codes relevant to autism.
374 This allows us to better capture people on the spectrum and, thus, better represent the autistic
375 population in England.

376 A limitation is that, in earlier stages of the pandemic, community incidence of COVID-19 is likely
377 underreported as testing was not yet standard practice and availability of tests was limited. However,
378 it is likely that testing rates do not differ between people with and without autism. Similarly, case

379 fatality rates may be inflated due to lack of testing in these earlier stages. Additionally, whilst the
380 dataset makes use of a whole-country population dataset, it should be noted that the final merged
381 dataset contained a larger number of records than the recorded population size of England. This may
382 be due to duplication of records, incorrect matching of NHS and death records, or people not
383 registered as living in the UK receiving NHS treatment. However, effects on results reported in this
384 study are likely to be minimal due to its use of rates and ratios, though caution should be exercised
385 when interpreting absolute values.

386 Due to the use of autism identification through SNOMED CT diagnosis codes through primary care
387 data, it is possible that the autistic study population does not fully capture the autistic population in
388 England. Previous studies have indeed identified gaps in identification of autistic people over 30 years
389 old within primary care (37). Moreover, it is possible that some autistic individuals are not registered
390 with primary care and thus were not identified in this dataset.

391

392 **Conclusion**

393 To conclude, our results show that autistic adults are at higher risk of hospitalisation or death due to
394 COVID-19 as compared to the general population. Whilst demographic and clinical risk factors are
395 similar for the autistic and general population, our results suggest that complex multimorbidity and
396 prescription medication class may be of particular importance for the autistic population and should
397 be further researched.

398 **Declarations**

399 **Ethics approval and consent to participate**

400 The North-East – Newcastle and North Tyneside 2 research ethics committee provided ethical
401 approval for the CVD-COVID-UK/COVID-IMPACT research programme (REC No 20/NE/0161) to access,
402 within secure trusted research environments, unconsented, whole-population, de-identified data
403 from electronic health records collected as part of patients' routine healthcare. The need for informed
404 consent was waived by the North-East – Newcastle and North Tyneside 2 research ethics committee.
405 All methods were carried out in accordance with relevant guidelines and regulations.

406 **Availability of data and materials**

407 The data used in this study are available in NHS England's Secure Data Environment (SDE) service for
408 England, but as restrictions apply they are not publicly available (49).

409 The CVD-COVID-UK/COVID-IMPACT programme led by the BHF Data Science Centre (50) received
410 approval to access data in NHS England's SDE service for England from the Independent Group

411 Advising on the Release of Data (IGARD) (51) via an application made in the Data Access Request
412 Service (DARS) Online system (ref. DARS-NIC-381078-Y9C5K) (52).

413 The CVD-COVID-UK/COVID-IMPACT Approvals & Oversight Board (31) subsequently granted
414 approval to this project to access the data within NHS England's SDE service for England. The de-
415 identified data used in this study were made available to accredited researchers only. Those wishing
416 to gain access to the data should contact bhfdsc@hdruk.ac.uk in the first instance.

417 **Competing interests**

418 The authors declare that they have no competing interests.

419 **Funding**

420 The British Heart Foundation Data Science Centre (grant No SP/19/3/34678, awarded to Health Data
421 Research (HDR) UK) funded co-development (with NHS England) of the Secure Data Environment
422 service for England, provision of linked datasets, data access, user software licences, computational
423 usage, and data management and wrangling support, with additional contributions from the HDR UK
424 Data and Connectivity component of the UK Government Chief Scientific Adviser's National Core
425 Studies programme to coordinate national COVID-19 priority research. Consortium partner
426 organisations funded the time of contributing data analysts, biostatisticians, epidemiologists, and
427 clinicians.

428 The associated costs of accessing data in NHS England's Secure Data Environment service for England,
429 for analysts working on this study, were funded by the Data and Connectivity National Core Study, led
430 by Health Data Research UK in partnership with the Office for National Statistics, which is funded by
431 UK Research and Innovation (grant ref: MC_PC_20058).

432 The Baily Thomas Charitable Fund funded staff (FS) time on this project.

433

434 **Acknowledgements**

435 This work was carried out with the support of the BHF Data Science Centre led by HDR UK (BHF Grant
436 no. SP/19/3/34678). This study makes use of de-identified data held in NHS England's Secure Data
437 Environment service for England and made available via the BHF Data Science Centre's CVD-COVID-
438 UK/COVID-IMPACT consortium. This work uses data provided by patients and collected by the NHS as
439 part of their care and support. We would also like to acknowledge all data providers who make health
440 relevant data available for research.

441 The authors would like to thank The Baily Thomas Charitable Fund for funding staff costs on this
442 study.

443 **Data Availability Statement**

444 For the purpose of open access, the authors have applied a Creative Commons Attribution (CC BY)
445 licence to any Author Accepted Manuscript version arising from this submission.

446

447 **References**

- 448 1. GOV.UK. 2 Years of COVID-19 on GOV.UK - Government Digital Service [Internet]. [cited 2023
449 Sep 7]. Available from: <https://gds.blog.gov.uk/2022/07/25/2-years-of-covid-19-on-gov-uk/>
- 450 2. Zhou Y, Chi J, Lv W, Wang Y. Obesity and diabetes as high-risk factors for severe coronavirus
451 disease 2019 (Covid-19). *Diabetes Metab Res Rev* [Internet]. 2021 Feb 1 [cited 2023 Jul
452 16];37(2):e3377. Available from: <https://onlinelibrary.wiley.com/doi/full/10.1002/dmrr.3377>
- 453 3. Li J, Huang DQ, Zou B, Yang H, Hui WZ, Rui F, et al. Epidemiology of COVID-19: A systematic
454 review and meta-analysis of clinical characteristics, risk factors, and outcomes. *J Med Virol*
455 [Internet]. 2021 Mar 1 [cited 2023 Jul 16];93(3):1449–58. Available from:
456 <https://onlinelibrary.wiley.com/doi/full/10.1002/jmv.26424>
- 457 4. Constantino JN, Sahin M, Piven J, Rodgers R, Tschida J. The Impact of COVID-19 on Individuals
458 with Intellectual and Developmental Disabilities: Clinical and Scientific Priorities. *Am J*
459 *Psychiatry* [Internet]. 2020 Nov 1 [cited 2023 Jul 16];177(11):1091–3. Available from:
460 <https://ajp.psychiatryonline.org/doi/10.1176/appi.ajp.2020.20060780>
- 461 5. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th
462 ed. Arlington: American Psychiatric Publishing; 2013.
- 463 6. Lima ME de S, Barros LCM, Aragão GF. Could autism spectrum disorders be a risk factor for
464 COVID-19? *Med Hypotheses*. 2020 Nov 1;144:109899.
- 465 7. Croonenberghs J, Bosmans E, Deboutte D, Kenis G, Maes M. Activation of the Inflammatory
466 Response System in Autism. *Neuropsychobiology* [Internet]. 2002 Jan 1 [cited 2023 Jul
467 17];45(1):1–6. Available from: <https://dx.doi.org/10.1159/000048665>
- 468 8. Brondino N, Bertoglio F, Forneris F, Faravelli S, Borghesi A, Damiani S, et al. A Pilot Study on
469 Covid and Autism: Prevalence, Clinical Presentation and Vaccine Side Effects. *Brain Sci* 2021,
470 Vol 11, Page 860 [Internet]. 2021 Jun 28 [cited 2023 Jul 17];11(7):860. Available from:
471 <https://www.mdpi.com/2076-3425/11/7/860/htm>
- 472 9. Vai B, Mazza MG, Delli Colli C, Foiselle M, Allen B, Benedetti F, et al. Mental Disorders and
473 Risk of Covid-19 Related Mortality, Hospitalization and Intensive Care Unit Admission: A
474 Systematic Review and Meta-Analysis. *SSRN Electron J*. 2021 May 15;
- 475 10. Toubasi AA, AbuAnzeh RB, Tawileh HBA, Aldebei RH, Alryalat SAS. A meta-analysis: The
476 mortality and severity of COVID-19 among patients with mental disorders. *Psychiatry Res*
477 [Internet]. 2021 May 1 [cited 2023 Jul 18];299:113856. Available from:
478 [/pmc/articles/PMC7927594/](https://pmc/articles/PMC7927594/)
- 479 11. Rydzewska E, Dunn K, Cooper SA. Umbrella systematic review of systematic reviews and
480 meta-analyses on comorbid physical conditions in people with autism spectrum disorder. *Br J*
481 *Psychiatry* [Internet]. 2021 Jan 1 [cited 2023 Jul 17];218(1):10–9. Available from:
482 [https://www.cambridge.org/core/journals/the-british-journal-of-psychiatry/article/umbrella-](https://www.cambridge.org/core/journals/the-british-journal-of-psychiatry/article/umbrella-systematic-review-of-systematic-reviews-and-metaanalyses-on-comorbid-physical-conditions-in-people-with-autism-spectrum-)
483 [systematic-review-of-systematic-reviews-and-metaanalyses-on-comorbid-physical-](https://www.cambridge.org/core/journals/the-british-journal-of-psychiatry/article/umbrella-systematic-review-of-systematic-reviews-and-metaanalyses-on-comorbid-physical-conditions-in-people-with-autism-spectrum-)
484 [conditions-in-people-with-autism-spectrum-](https://www.cambridge.org/core/journals/the-british-journal-of-psychiatry/article/umbrella-systematic-review-of-systematic-reviews-and-metaanalyses-on-comorbid-physical-conditions-in-people-with-autism-spectrum-)


- 485 disorder/EC3473487B4B26DA18E1BFB634BB2390
- 486 12. Hossain MM, Khan N, Sultana A, Ma P, McKyer ELJ, Ahmed HU, et al. Prevalence of comorbid
487 psychiatric disorders among people with autism spectrum disorder: An umbrella review of
488 systematic reviews and meta-analyses. Vol. 287, Psychiatry Research. 2020.
- 489 13. Eshraghi AA, Li C, Alessandri M, Messinger DS, Eshraghi RS, Mittal R, et al. COVID-19:
490 overcoming the challenges faced by individuals with autism and their families. The Lancet
491 Psychiatry [Internet]. 2020 Jun 1 [cited 2023 Jul 17];7(6):481–3. Available from:
492 <http://www.thelancet.com/article/S2215036620301978/fulltext>
- 493 14. Mutluer T, Doenyas C, Aslan Genc H. Behavioral Implications of the Covid-19 Process for
494 Autism Spectrum Disorder, and Individuals' Comprehension of and Reactions to the Pandemic
495 Conditions. Front Psychiatry. 2020 Nov 16;11:561882.
- 496 15. Iaccarino G, Grassi G, Borghi C, Ferri C, Salvetti M, Volpe Massimo M. Age and Multimorbidity
497 Predict Death Among COVID-19 Patients. Hypertension [Internet]. 2020 Aug 1 [cited 2023 Jul
498 17];76(2). Available from:
499 <https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.120.15324>
- 500 16. McKeigue PM, Kennedy S, Weir A, Bishop J, McGurnaghan SJ, McAllister D, et al. Relation of
501 severe COVID-19 to polypharmacy and prescribing of psychotropic drugs: the REACT-SCOT
502 case-control study. BMC Med [Internet]. 2021 Dec 1 [cited 2023 Jul 17];19(1):1–11. Available
503 from: <https://bmcmmedicine.biomedcentral.com/articles/10.1186/s12916-021-01907-8>
- 504 17. Spencer D, Marshall J, Post B, Kulakodlu M, Newschaffer C, Dennen T, et al. Psychotropic
505 Medication Use and Polypharmacy in Children With Autism Spectrum Disorders. Pediatrics
506 [Internet]. 2013 Nov 1 [cited 2023 Jul 17];132(5):833–40. Available from:
507 </pediatrics/article/132/5/833/31738/Psychotropic-Medication-Use-and-Polypharmacy-in>
- 508 18. Lake JK, Balogh R, Lunskey Y. Polypharmacy profiles and predictors among adults with autism
509 spectrum disorders. Res Autism Spectr Disord. 2012 Jul 1;6(3):1142–9.
- 510 19. Vohra R, Madhavan S, Sambamoorthi U, StPeter C, Poe S, Dwibedi N, et al. Prescription Drug
511 Use and Polypharmacy Among Medicaid-Enrolled Adults with Autism: A Retrospective Cross-
512 Sectional Analysis. Drugs - Real World Outcomes [Internet]. 2016 Dec 1 [cited 2023 Jul
513 17];3(4):409–25. Available from: [https://link.springer.com/article/10.1007/s40801-016-0096-](https://link.springer.com/article/10.1007/s40801-016-0096-z)
514 [z](https://link.springer.com/article/10.1007/s40801-016-0096-z)
- 515 20. Laporte JR, Healy D. Medications compromising Covid infections [Internet]. RxISK |
516 Prescription Drug Side Effects. 2020 [cited 2022 Aug 23]. Available from:
517 <https://rxisk.org/medications-compromising-covid-infections/>
- 518 21. May M, Slitzky M, Rostama B, Barlow D, Houseknecht KL. Antipsychotic-induced immune
519 dysfunction: A consideration for COVID-19 risk. Brain, Behav Immun - Heal. 2020 Jul
520 1;6:100097.
- 521 22. Reilev M, Kristensen KB, Pottegård A, Lund LC, Hallas J, Ernst MT, et al. Characteristics and
522 predictors of hospitalization and death in the first 11 122 cases with a positive RT-PCR test for
523 SARS-CoV-2 in Denmark: a nationwide cohort. Int J Epidemiol [Internet]. 2020 Oct 1 [cited
524 2023 Jul 17];49(5):1468–81. Available from: <https://dx.doi.org/10.1093/ije/dyaa140>
- 525 23. Poblador-Plou B, Carmona-Pérez J, Ioakeim-Skoufa I, Poncel-Falcó A, Bliiek-Bueno K, Cano-Del
526 Pozo M, et al. Baseline Chronic Comorbidity and Mortality in Laboratory-Confirmed COVID-19
527 Cases: Results from the PRECOVID Study in Spain. Int J Environ Res Public Heal 2020, Vol 17,
528 Page 5171 [Internet]. 2020 Jul 17 [cited 2023 Jul 17];17(14):5171. Available from:

- 529 <https://www.mdpi.com/1660-4601/17/14/5171/htm>
- 530 24. Cantudo-Cuenca MD, Gutiérrez-Pizarra A, Pinilla-Fernández A, Contreras-Macías E,
531 Fernández-Fuertes M, Lao-Domínguez FA, et al. Drug–drug interactions between treatment
532 specific pharmacotherapy and concomitant medication in patients with COVID-19 in the first
533 wave in Spain. *Sci Reports* 2021 111 [Internet]. 2021 Jun 14 [cited 2023 Jul 17];11(1):1–8.
534 Available from: <https://www.nature.com/articles/s41598-021-91953-2>
- 535 25. Plasencia-García BO, Rodríguez-Menéndez G, Rico-Rangel MI, Rubio-García A, Torelló-Iserte J,
536 Crespo-Facorro B. Drug-drug interactions between COVID-19 treatments and antipsychotics
537 drugs: integrated evidence from 4 databases and a systematic review. *Psychopharmacology*
538 (Berl) [Internet]. 2021 Feb 1 [cited 2023 Jul 17];238(2):329–40. Available from:
539 <https://pubmed.ncbi.nlm.nih.gov/33410987/>
- 540 26. Jeste S, Hyde C, Distefano C, Halladay A, Ray S, Porath M, et al. Changes in access to
541 educational and healthcare services for individuals with intellectual and developmental
542 disabilities during COVID-19 restrictions. *J Intellect Disabil Res* [Internet]. 2020 Nov 1 [cited
543 2023 Jul 17];64(11):825–33. Available from:
544 <https://onlinelibrary.wiley.com/doi/full/10.1111/jir.12776>
- 545 27. Sosenko F, Mackay D, Bhautesh DJ, Fleming M, Pell JP, Hatton C, et al. Understanding covid-
546 19 outcomes among people with Intellectual Disabilities in England. *BMC Public Health*.
547 2023;23(2099). Available from: <https://doi.org/10.1186/s12889-023-16993-x>
- 548 28. Henderson A, Fleming M, Cooper SA, Pell JP, Melville C, MacKay DF, et al. COVID-19 infection
549 and outcomes in a population-based cohort of 17 203 adults with intellectual disabilities
550 compared with the general population. *J Epidemiol Community Heal* [Internet]. 2022 Jun 1
551 [cited 2023 Jul 17];76(6):550–5. Available from: <https://jech.bmj.com/content/76/6/550>
- 552 29. Gardner W, States D, Bagley N. The Coronavirus and the Risks to the Elderly in Long-Term
553 Care. <https://doi.org/10.1080/0895942020201750543> [Internet]. 2020 Jul 3 [cited 2023 Jul
554 17];32(4–5):310–5. Available from:
555 <https://www.tandfonline.com/doi/abs/10.1080/08959420.2020.1750543>
- 556 30. Krieger I, Erez G, Weinstein O, Cohen AD, Tzur Bitan D. COVID-19 Morbidity Among
557 Individuals with Autistic Spectrum Disorder: A Matched Controlled Population-Based Study. *J*
558 *Autism Dev Disord* [Internet]. 2023 Feb 1 [cited 2023 Jul 17];53(2):789–94. Available from:
559 <https://link.springer.com/article/10.1007/s10803-021-05187-2>
- 560 31. British Heart Foundation Data Science Centre [Internet]. Available from:
561 <https://bhfdatasciencecentre.org/areas/cvd-covid-uk-covid-impact/>
- 562 32. Cassell A, Edwards D, Harshfield A, Rhodes K, Brimicombe J, Payne R, et al. The epidemiology
563 of multimorbidity in primary care: a retrospective cohort study. *Br J Gen Pract* [Internet].
564 2018 Apr 1 [cited 2023 Jul 17];68(669):e245–51. Available from:
565 <https://bjgp.org/content/68/669/e245>
- 566 33. Public Health England. Deaths of people identified as having learning disabilities with COVID-
567 19 in England in the spring of 2020 [Internet]. London; 2020. Available from:
568 [https://www.gov.uk/government/publications/covid-19-deaths-of-people-with-learning-](https://www.gov.uk/government/publications/covid-19-deaths-of-people-with-learning-disabilities)
569 [disabilities](https://www.gov.uk/government/publications/covid-19-deaths-of-people-with-learning-disabilities) (2020).
- 570 34. Kinnear D, Morrison J, Allan L, Henderson A, Smiley E, Cooper SA. Prevalence of physical
571 conditions and multimorbidity in a cohort of adults with intellectual disabilities with and
572 without Down syndrome: cross-sectional study. *BMJ Open* [Internet]. 2018 Feb 1 [cited 2023
573 Jul 3];8(2):18292. Available from: [/pmc/articles/PMC5829598/](https://pmc/articles/PMC5829598/)

- 574 35. Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic
575 review of definitions. *BMC Geriatr* [Internet]. 2017 Oct 10 [cited 2023 Jul 17];17(1):1–10.
576 Available from: <https://bmcgeriatr.biomedcentral.com/articles/10.1186/s12877-017-0621-2>
- 577 36. Forsyth L, Mcsorley M, Rydzewska E. All-cause and cause-specific mortality in people with
578 autism spectrum disorder: A systematic review. *Res Autism Spectr Disord* [Internet]. 2023
579 [cited 2023 Jul 3];105:102165. Available from: <http://creativecommons.org/licenses/by/4.0/>
- 580 37. Mehta H, Glover G. Psychotropic drugs and people with learning disabilities or autism
581 [Internet]. Public Health England. 2019. Available from:
582 [https://www.gov.uk/government/publications/psychotropic-drugs-and-people-with-learning-](https://www.gov.uk/government/publications/psychotropic-drugs-and-people-with-learning-disabilities-or-autism/psychotropic-drugs-and-people-with-learning-disabilities-or-autism-discussion#citation)
583 [disabilities-or-autism/psychotropic-drugs-and-people-with-learning-disabilities-or-autism-](https://www.gov.uk/government/publications/psychotropic-drugs-and-people-with-learning-disabilities-or-autism/psychotropic-drugs-and-people-with-learning-disabilities-or-autism-discussion#citation)
584 [discussion#citation](https://www.gov.uk/government/publications/psychotropic-drugs-and-people-with-learning-disabilities-or-autism/psychotropic-drugs-and-people-with-learning-disabilities-or-autism-discussion#citation)
- 585 38. Russell G, Stapley S, Newlove-Delgado T, Salmon A, White R, Warren F, et al. Time trends in
586 autism diagnosis over 20 years: a UK population-based cohort study. *J Child Psychol*
587 *Psychiatry Allied Discip*. 2022 Jun 1;63(6):674–82.
- 588 39. Github analysis plan [Internet]. Available from: https://github.com/BHFDSC/CCU030_02
- 589 40. Glover G, Williams R, Branford D, Avery R, Chauhan U, Hoghton M, et al. Prescribing of
590 psychotropic drugs to people with learning disabilities and/or autism by general practitioners
591 in England [Internet]. 2015. Available from:
592 <http://webarchive.nationalarchives.gov.uk/20160704152031>
- 593 41. Carthy E, Ross C, Murphy D. Psychotropic medication prescribing in people with autism
594 spectrum disorders with and without psychiatric comorbidity. [cited 2023 Oct 23]; Available
595 from: <https://doi.org/10.1192/bja.2021.32>
- 596 42. Rahimi E, Hashemi Nazari SS. A detailed explanation and graphical representation of the
597 Blinder-Oaxaca decomposition method with its application in health inequalities. *Emerg*
598 *Themes Epidemiol* [Internet]. 2021 Dec 1 [cited 2023 Aug 15];18(1):1–15. Available from:
599 <https://ete-online.biomedcentral.com/articles/10.1186/s12982-021-00100-9>
- 600 43. Lai MC, Lombardo M V., Baron-Cohen S. Autism. *Lancet*. 2014 Mar 8;383(9920):896–910.
- 601 44. Nicolaidis C, Raymaker D, McDonald K, Dern S, Boisclair WC, Ashkenazy E, et al. Comparison
602 of healthcare experiences in autistic and non-autistic adults: A cross-sectional online survey
603 facilitated by an academic-community partnership. *J Gen Intern Med* [Internet]. 2013 Jun 21
604 [cited 2023 Jul 18];28(6):761–9. Available from:
605 <https://link.springer.com/article/10.1007/s11606-012-2262-7>
- 606 45. Strydom A, Corcoran E, Rebillat AS. The COVID-19 pandemic should be last orders for poor
607 care of people with neurodevelopmental disorders. *Br J Psychiatry* [Internet]. 2021 Jun 1
608 [cited 2023 Jul 18];218(6):302–4. Available from:
609 [https://www.cambridge.org/core/journals/the-british-journal-of-psychiatry/article/covid19-](https://www.cambridge.org/core/journals/the-british-journal-of-psychiatry/article/covid19-pandemic-should-be-last-orders-for-poor-care-of-people-with-neurodevelopmental-disorders/A2776C8EDCCE04C4797EB1B528F1E8F7)
610 [pandemic-should-be-last-orders-for-poor-care-of-people-with-neurodevelopmental-](https://www.cambridge.org/core/journals/the-british-journal-of-psychiatry/article/covid19-pandemic-should-be-last-orders-for-poor-care-of-people-with-neurodevelopmental-disorders/A2776C8EDCCE04C4797EB1B528F1E8F7)
611 [disorders/A2776C8EDCCE04C4797EB1B528F1E8F7](https://www.cambridge.org/core/journals/the-british-journal-of-psychiatry/article/covid19-pandemic-should-be-last-orders-for-poor-care-of-people-with-neurodevelopmental-disorders/A2776C8EDCCE04C4797EB1B528F1E8F7)
- 612 46. Saqr Y, Braun E, Porter K, Barnette D, Hanks C. Addressing medical needs of adolescents and
613 adults with autism spectrum disorders in a primary care setting. *Autism* [Internet]. 2018 Jan 1
614 [cited 2023 Jul 18];22(1):51–61. Available from:
615 <https://journals.sagepub.com/doi/10.1177/1362361317709970>
- 616 47. Nakhaee HI, Zangiabadian MI, Bayati R, Rahmanian M, Ghaffari Jolfayi A, Rakhshanderou S.
617 The effect of antidepressants on the severity of COVID-19 in hospitalized patients: A

- 618 systematic review and meta-analysis. 2022 [cited 2023 Jul 18]; Available from:
619 <https://doi.org/10.1371/journal.pone.0267423>
- 620 48. Hoertel N, Sánchez-Rico M, Vernet R, Nathanaël Beeker •, Jannot A-S, Neuraz A, et al.
621 Association between antidepressant use and reduced risk of intubation or death in
622 hospitalized patients with COVID-19: results from an observational study. *Mol Psychiatry*
623 [Internet]. 2021 [cited 2023 Jul 18];26:5199–212. Available from:
624 <https://doi.org/10.1038/s41380-021-01021-4>
- 625 49. NHS England Secure Data Environment Service [Internet]. Available from:
626 <https://digital.nhs.uk/services/secure-data-environment-service>
- 627 50. BHF Data Science Centre [Internet]. Available from: <https://bhfdatasciencecentre.org/>
- 628 51. NHS England IGARD [Internet]. Available from: [https://digital.nhs.uk/about-nhs-](https://digital.nhs.uk/about-nhs-digital/corporate-information-and-documents/independent-group-advising-on-the-release-of-data)
629 [digital/corporate-information-and-documents/independent-group-advising-on-the-release-](https://digital.nhs.uk/about-nhs-digital/corporate-information-and-documents/independent-group-advising-on-the-release-of-data)
630 [of-data](https://digital.nhs.uk/about-nhs-digital/corporate-information-and-documents/independent-group-advising-on-the-release-of-data)
- 631 52. NHS Digital DARS [Internet]. Available from: [https://digital.nhs.uk/services/data-access-](https://digital.nhs.uk/services/data-access-request-service-dars/dars-products-and-services)
632 [request-service-dars/dars-products-and-services](https://digital.nhs.uk/services/data-access-request-service-dars/dars-products-and-services)).
- 633 53. Kenny L, Hattersley C, Molins B, Buckley C, Povey C, Pellicano E. Which terms should be used
634 to describe autism? Perspectives from the UK autism community.
635 <http://dx.doi.org/10.1177/1362361315588200> [Internet]. 2015 Jul 1 [cited 2023 Jul
636 18];20(4):442–62. Available from:
637 [https://journals.sagepub.com/doi/10.1177/1362361315588200?url_ver=Z39.88-](https://journals.sagepub.com/doi/10.1177/1362361315588200?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub++0pubmed)
638 [2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub++0pubmed](https://journals.sagepub.com/doi/10.1177/1362361315588200?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub++0pubmed)
- 639

Figure 1. Visualisation of Blinder-Oaxaca Decomposition analysis.



Tables

Table 1. Demographic and health characteristics of autistic and general population people hospitalised with a registered positive COVID-19 test.

	General population (n = 8,425,470)	Autistic population (n = 32,375)			
		Adjusted	P-value	Unadjusted	P-value
Age [Mdn., IQR]	41.8 [30.0, 55.0]	-	-	24.9 [21.0, 31.5]	<0.001
Female (%)	54.0	33.7	<0.001	33.4	<0.001
Mean IMD decile (SD)	5.4 (2.9)	5.0 (2.8)	<0.001	5.1 (2.9)	<0.001
Ethnicity (%)			<0.001		<0.001
White	82.7	93.5		92.0	
Asian	9.2	2.2		2.4	
Black	3.7	1.6		2.0	
Mixed	1.9	1.6		2.4	
Other	2.4	1.1		1.3	
Vaccine			0.8		<0.001
AstraZeneca	21.2	23.4		30.1	
Moderna	3.4	3.1		7.6	
Pfizer	26.4	24.4		62.2	
Vaccine doses			>0.9		<0.001
0	49.3	49.1		50.8	
1	18.3	18.4		19.4	
2	32.5	32.5		29.8	
Total number of prescribed medications			<0.001		<0.001
0	55.8	36.1		53.4	
1-3	23.0	24.4		25.8	
4-6	9.3	14.5		10.4	
7-9	4.9	9.0		4.9	
10+	7.0	16.1		5.4	
Mean prescription medications (SD)	2.9 (4.5)	5.1 (6.0)	<0.001	2.7 (3.6)	0.002
Polypharmacy (%)	21.2	39.5	<0.001	20.8	0.14
Medications split by class			<0.001		-
On Psychotropics (%)					
No	80.9	49.7		-	
Yes	19.1	50.3		-	
Antipsychotics (%)	1.3	12.7	<0.001	-	-

Antidepressants (%)	17.1	45.1	<0.001	-	-
Anticonvulsants (%)	3.9	11.7	<0.001	-	-
Morbidity					
Mean LTCs (SD)	1.0 (3.0)	2.4 (4.0)	<0.001	1.2 (2.7)	<0.001
Multimorbidity (%)	11.9	24.3	<0.001	12.4	<0.001

Table 2. Standardised Incidence Ratios for autistic adults with general population as reference.

	COVID-19 Hospitalisation				Severe COVID-19			
	Observed	Expected	Excess	SIR [95% CI]	Observed	Expected	Excess	SIR [95% CI]
Mar-Dec 2020	372	234	138	1.6 [1.4, 1.7]	382	244	138	1.6 [1.4, 1.7]
Jan-Dec 2021	603	461	142	1.3 [1.2, 1.4]	620	469	151	1.3 [1.2, 1.4]

Table 3. Age Standardised Mortality Rates (ASMR) for the adult autistic and general population in study sample as compared to the European Standard Population 2013. Second column shows Standardised Mortality Ratios (SMR) for the autistic population as compared to the general population for the study sample only. Observed, expected and excess mortality for SMRs are shown.

	ASMR [95% CI]		SMR [95% CI]			
	Autistic population	General population	Autistic population	Observed	Expected	Excess
Mar-Dec 2020	278.9 [278, 278]	166.2 [166, 166]	1.52 [1.04, 2.0]	39	25.6	13.4
Jan-Dec 2021	271.5 [271, 271]	143.1 [143, 143]	1.34 [0.93, 1.74]	42	31.5	10.5

Table 4. Results from the logistic models A and B fit to the autistic and general population separately.

Predictors	Model A				Model B			
	General population		Autistic population		General population		Autistic population	
	Coefficient [95% CI]	P-value	Coefficient [95% CI]	P-value	Coefficient [95% CI]	P-value	Coefficient [95% CI]	P-value
Age at COVID-19	1.039 [1.039, 1.039]	<.001	1.037 [1.031, 1.042]	<.001	1.044 [1.044, 1.044]	<.001	1.038 [1.033, 1.043]	<.001
Female	0.713 [0.705, 0.720]	<.001	0.729 [0.570, 0.888]	<.001	0.756 [0.749, 0.764]	<.001	0.808 [0.648, 0.968]	.01
IMD decile	0.969 [0.968, 0.971]	<.001	1.002 [0.976, 1.029]	.86	0.964 [0.963, 0.965]	<.001	-	-
Ethnicity								
White	(base)							
Asian	1.770 [1.758, 1.781]	<.001	1.695 [1.280, 2.109]	.01	1.798 [1.786, 1.809]	<.001	1.587 [1.173, 2.001]	.03
Black	2.162 [2.145, 2.179]	<.001	1.468 [1.009, 1.926]	.10	2.075 [2.058, 2.091]	<.001	1.313 [0.856, 1.770]	.24
Mixed	1.654 [1.625, 1.683]	<.001	1.253 [0.798, 1.709]	.33	1.622 [1.594, 1.650]	<.001	1.279 [0.830, 1.729]	.28
Other	2.119 [2.096, 2.142]	<.001	1.372 [0.755, 1.990]	.32	2.005 [1.982, 2.027]	<.001	1.362 [0.749, 1.975]	.32
Vaccine								
Number of vaccine doses	0.740 [0.724, 0.755]	<.001	0.724 [0.370, 1.077]	.07	0.747 [0.731, 0.763]	<.001	0.730 [0.367, 1.093]	.09
AstraZeneca	0.489 [0.459, 0.520]	<.001	0.539 [- 0.149, 1.227]	.07	0.465 [0.434, 0.497]	<.001	0.508 [- 0.199, 1.216]	.06
Pfizer	0.297 [0.273, 0.321]	<.001	0.268 [- 0.291, 0.828]	<.001	0.285 [0.260, 0.310]	<.001	0.253 [- 0.323, 0.829]	<.001
Moderna	0.122 [0.062, 0.182]	<.001	0.203 [- .0733, 1.139]	.001	0.118 [0.058, 0.178]	<.001	0.187 [- 0.765, 1.139]	.001
Interactions								

Count of long-term conditions	1.550 [1.548, 1.551]	<.001	1.570 [1.543, 1.597]	<.001	1.370 [1.369, 1.370]	<.001	1.436 [1.419, 1.453]	<.001
Count of prescription medicines	1.101 [1.100, 1.102]	<.001	1.084 [1.057, 1.111]	<.001	-	-	-	-
Interaction of the above two counts	0.984 [0.984, 0.984]	<.001	0.985 [0.982, 0.988]	<.001	-	-	-	-
Prescription medication by class								
Antipsychotic	-	-	-	-	1.713 [1.693, 1.733]	<.001	1.262 [1.044, 1.479]	.03
Antidepressant	-	-	-	-	0.867 [0.857, 0.876]	<.001	0.643 [0.475, 0.811]	<.001
Anticonvulsant	-	-	-	-	1.082 [1.068, 1.095]	<.001	1.028 [0.805, 1.250]	.81
Constant	0.005 [-0.010, 0.020]	<.001	0.004 [-0.252, 0.260]	<.001	0.006 [-0.009, 0.020]	<.001	0.006 [-0.201, 0.214]	<.001
Observations	8,259,596	-	31,758	-	8,259,596	-	31,782	-

Table 5. Results from the Cox proportional hazards model for model A and B.

Model A								
Variables	General population				Autistic population			
	β	SE	Exp(β) [95% CI lower, upper]	P-value	β	SE	Exp(β) [95% CI lower, upper]	P-value
Age at COVID-19	.03	.0001	1.03 [1.03, 1.03]	<.001	.03	.003	1.03 [1.02, 1.03]	<.001
Female	-.37	.003	.69 [.69, .69]	<.001	-.28	.087	.75 [.63, .89]	.001
IMD decile	-.03	.0006	.97 [.97, .98]	<.001	-			
Ethnicity								
White	(base)							
Asian	.51	.005	1.67 [1.65, 1.69]	<.001	.76	.215	2.13 [1.40, 3.24]	<.001
Black	.59	.008	1.81 [1.78, 1.84]	<.001	.21	.240	1.24 [.77, 1.98]	.37
Mixed	.39	.014	1.47 [1.43, 1.51]	<.001	-.14	.282	.87 [.50, 1.51]	.61
Other	.59	.011	1.81 [1.77, 1.85]	<.001	.01	.337	1.01 [.52, 1.95]	.98
Vaccinations								
Number of doses	-.23	.008	.80 [.78, .81]	<.001	-.48	.205	.62 [.41, .92]	.01
AstraZeneca	-.48	.015	.62 [.60, .64]	<.001	-.09	.394	.92 [.42, 1.99]	.83
Pfizer	-.95	.012	.39 [.38, .40]	<.001	-1.03	.314	.36 [.19, .66]	.001
Moderna	-1.93	.034	.15 [.14, .16]	<.001	-2.04	.748	.13 [.03, .56]	.006
Interactions								
Count of long-term conditions	0.22	.0006	1.25 [1.25, 1.25]	<.001	.35	.012	1.42 [1.38, 1.45]	<.001
Count of prescription medicines	.03	.0006	1.03 [1.03, 1.03]	<.001	.09	.015	1.09 [1.06, 1.12]	<.001
Interaction of the above two counts	-.006	.00006	.99 [.99, .99]	<.001	-.01	.002	.99 [.99, .99]	<.001

Model B								
Variables	General population				Autistic population			
	β	SE	HR [95% CI lower, upper]	P-value	β	SE	HR [95% CI lower, upper]	P-value
Age at COVID-19	.025	.0001	1.03 [1.03, 1.03]	<.001	.03	.002	1.03 [1.02, 1.03]	<.001
Female	-.35	.003	.70 [.70, .71]	<.001	-.19	.086	.83 [.70, .98]	.03
IMD decile	-.03	.001	.97 [.97, .97]	<.001			-	
Ethnicity								
White	(base)							
Asian	.49	.005	1.64 [1.62, 1.65]	<.001	.77	.215	2.14 [1.41, 3.28]	<.001
Black	.57	.008	1.77 [1.74, 1.79]	<.001	.17	.241	1.19 [.74, 1.90]	.48
Mixed	.37	.014	1.45 [1.41, 1.49]	<.001	-.05	.282	.95 [.54, 1.65]	.85
Other	.58	.011	1.78 [1.75, 1.82]	<.001	.11	.337	1.12 [.58, 2.16]	.75
Vaccinations								
Number of doses	-.22	.008	.80 [.79, .81]	<.001	-.45	.203	.64 [.43, .95]	.03
AstraZeneca	-.48	.015	.62 [.60, .64]	<.001	-.15	.390	.86 [.40, 1.85]	.70
Pfizer	-.95	.012	.39 [.38, .40]	<.001	-1.12	.314	.33 [.18, .60]	<.001
Moderna	-1.95	.034	.14 [.13, .15]	<.001	-2.13	.750	.12 [.03, .52]	.004
LTCs								
Count of long-term conditions	.17	.0004	1.19 [1.19, 1.19]	<.001	.28	.008	1.32 [1.30, 1.34]	<.001
Prescribed medications by class								
Antipsychotic medication	-.01	.007	.99 [.97, 1.0]	.07	.02	.115	1.02 [.82, 1.28]	.85
Antidepressive medication	-.17	.004	.85 [.84, .85]	<.001	-.24	.086	.78 [.66, .93]	.005
Anticonvulsive medication	.04	.005	1.04 [1.03, 1.05]	<.001	.11	.111	1.12 [.90, 1.39]	.30

Table 6. Results from the hierarchical logistic regression showing Pseudo R², Akaike Information Criterion (AIC) and Bayesian Information Criterion (BIC). Vaccine status is defined by the presence or absence of at least one COVID-19 vaccination.

	Autistic population			General population		
	Pseudo R2	AIC	BIC	Pseudo R2	AIC	BIC
Age	0.091	8353	8370	0.232	30871388	30871666
+ sex	0.093	8340	8365	0.234	30789963	30790381
+ ethnicity	0.094	8336	8394	0.241	30524687	30525662
+ IMD decile	0.095	8326	8393	0.248	30241212	30242327
+ vaccine status	0.145	7880	7989	0.297	28292202	28294012
+ LTC count	0.224	7160	7277	0.364	25565855	25567805
+ polypharmacy	0.225	7146	7272	0.369	25358599	25360689

